Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Theravance Biopharma (TBPH) Raw Materials (2016 - 2018)

Theravance Biopharma (TBPH) has disclosed Raw Materials for 6 consecutive years, with $10.8 million as the latest value for Q3 2018.

  • Quarterly Raw Materials rose 8.41% to $10.8 million in Q3 2018 from the year-ago period, while the trailing twelve-month figure was $10.8 million through Sep 2018, up 8.41% year-over-year, with the annual reading at $11.7 million for FY2017, 93.32% up from the prior year.
  • Raw Materials for Q3 2018 was $10.8 million at Theravance Biopharma, up from $10.6 million in the prior quarter.
  • The five-year high for Raw Materials was $11.7 million in Q4 2017, with the low at $4.0 million in Q1 2014.
  • Average Raw Materials over 5 years is $7.6 million, with a median of $6.9 million recorded in 2015.
  • The sharpest move saw Raw Materials fell 21.94% in 2016, then surged 93.32% in 2017.
  • Over 5 years, Raw Materials stood at $6.8 million in 2014, then grew by 0.57% to $6.9 million in 2015, then decreased by 11.68% to $6.1 million in 2016, then soared by 93.32% to $11.7 million in 2017, then fell by 8.05% to $10.8 million in 2018.
  • According to Business Quant data, Raw Materials over the past three periods came in at $10.8 million, $10.6 million, and $10.6 million for Q3 2018, Q2 2018, and Q1 2018 respectively.